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Abstract Binding of Trypanosoma cruzi trypomastigotes to
laminin is enhanced by galectin-3, a L-galactoside binding lectin.
The galectin-3 enhanced binding of trypanosomes to laminin is
inhibited by lactose. Co-immunoprecipitations indicate that
galectin-3 binds to the 45, 32 and 30 kDa trypanosome surface
proteins. Binding of galectin-3 to the 45, 32 and 30 kDa surface
proteins is inhibited by lactose. Polyclonal and a monoclonal
antibodies to galectin-3 immunoprecipitated a major 64 kDa
trypanosome surface protein. T. cruzi monoclonal antibody to
mucin recognized the 45 kDa surface protein. The 45, 32 and
30 kDa surface proteins interact with galectin-3 in order to
enhance trypanosome adhesion to laminin.
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1. Introduction
Trypanosoma cruzi, the protozoon that causes Chagas’ dis-
ease and a¡ects millions of people, must move through the
extracellular matrix before binding and entering host cells to
establish infection [1]. The molecules that facilitate T. cruzi
mobilization through the extracellular matrix are largely un-
known. In this study, we have explored the role of human
galectin-3 in enhancing the adhesion of invasive forms of
T. cruzi to extracellular matrix proteins. The disease is ac-
quired by entry of invasive trypomastigotes which are trans-
mitted by insect vectors, or by blood infected with trypomas-
tigotes during blood transfusion. This organism is now viewed
as an emerging human pathogen of HIV-1 infected individu-
als, since it induces dramatic brain pathology and earlier
death when associated with HIV-1 infection [2]. It has been
reported that T. cruzi trypomastigotes bind to extracellular
matrix components such as laminin [3], ¢bronectin [4], and
collagen [5]. However, the mechanisms of these interactions
are poorly understood. An understanding of how T. cruzi
surface molecules interact with galectin-3 to facilitate trypa-
nosome mobilization throughout the body may be critical for
the development of a molecular means of intervention against
this organism.
Human galectin-3 is a L-galactoside binding protein that
interacts with glycoproteins containing polylactosamine resi-
dues such as laminin [6]. Galectins have been found in several
species, including nematodes [7], mammals [6] and fungi [8].
Galectin-3 has been implicated in the regulation of adhesion
of human breast carcinoma cells to the extracellular matrix
[9]. Because galectin-3 is found on the cell surface of mamma-
lian cells, secreted and known to interact with extracellular
matrix proteins [6], we have investigated the role of galectin-
3 in the process of trypomastigote adhesion to the extracellu-
lar matrix.
In this paper we report the novel observation that the
cloned human galectin-3 speci¢cally binds to T. cruzi trypo-
mastigote surface proteins in order to enhance trypanosome
adhesion to laminin.
2. Materials and methods
2.1. Organism
The highly infective trypomastigote clone MMC 20A of the Tula-
huen strain of T. cruzi was used [10]. Pure culture trypomastigotes
were obtained from the supernatant of heart myoblast monolayers
[11]. Trypanosomes were washed with pyrogen free phosphate
bu¡ered saline (PBS) and resuspended at 1U108 organisms/ml in
PBS [12].
2.2. Reagents
Puri¢ed recombinant human galectin-3 was obtained as described
[13]. Polyclonal antibodies to puri¢ed galectin-3 were produced in
rabbits. A rat IgG monoclonal antibody (mAb) TIB 166 to galectin-
3 [14] was used. A C10 mAb to a surface T. cruzi trypomastigote
mucin and its isotype control [15] was kindly provided by Dr. M.
Fresno from Universidad Autonoma de Madrid, Spain.
2.3. T. cruzi trypomastigote adhesion assay
The e¡ect of galectin-3 in promoting adhesion of trypomastigotes
to laminin or collagen was studied in 8 well Lab-Tek chambers coated
with human laminin or collagen IV (1 Wg/well) in PBS overnight at
4‡C [16]. The free sites were blocked with bovine serum albumin [16].
Trypomastigotes (2U106) resuspended in PBS were added to wells
coated with laminin or collagen in triplicate for 30 min at 37‡C in
either the presence or absence of galectin-3 (100 Wg/ml). In control
assays, trypomastigotes were incubated with 100 Wg/ml of bovine se-
rum albumin. Wells were washed, ¢xed, stained with Giemsa stain
[17], and trypomastigotes were microscopically determined [18].
2.4. Sugar inhibition assay
In order to determine the speci¢city of galectin-3 mediating the
interaction between trypomastigotes and laminin, trypanosomes
were incubated in triplicate with galectin-3 in the presence of 50 mM
lactose or 50 mM sucrose (a control) as described in Section 2.3. To
evaluate the ability of lactose to inhibit the adherence of trypomasti-
gotes to laminin, increasing concentrations of lactose (1^100 Wg/ml)
were added to laminin coated wells in the presence of trypomastigotes
(2U106) and galectin-3 (100 Wg/ml).
2.5. Interactions between galectin-3 and T. cruzi surface proteins
analyzed by co-immunoprecipitations
The ability of galectin-3 to interact with trypomastigote surface
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proteins was investigated by co-immunoprecipitating solubilized bio-
tinylated trypomastigotes in the presence of galectin-3 using anti-ga-
lactin-3 polyclonal antibodies or pre-immune antibodies. The speci¢c-
ity of galectin-3 binding to T. cruzi surface proteins was investigated
by supplementing the reaction with either lactose or sucrose at a
concentration of 50 Wg/ml. Brie£y, 100 Wg of biotinylated trypomas-
tigotes [19] were pre-cleared with protein A Sepharose beads in im-
munoprecipitation bu¡er [20] and supernatants were incubated with
100 Wg/ml of galectin-3 in the same immunoprecipitation bu¡er con-
taining half the amount of detergents, in the presence of 50 mM
lactose or 50 mM sucrose for 12 h at 4‡C. Immunoprecipitation con-
trols using polyclonal antibodies to galectin-3 and biotinylated trypa-
nosome surface proteins in the absence of galectin-3 were performed.
Polyclonal antibodies to galactin-3 or pre-immune antibodies were
added to the reaction at the ¢nal dilution of 1:50 followed by protein
A Sepharose. The reaction was incubated overnight at 4‡C. Immuno-
precipitated proteins were separated by SDS^PAGE, blotted onto
nitrocellulose membranes, probed with avidin^horseradish peroxidase
(HRP) and developed by ECL (Amersham) [21]. To identify surface
trypomastigote proteins that interact with galectin-3, the blot of Fig.
4A, lane 1 was stripped and probed with either anti-T. cruzi mucin
mouse mAb or its isotype mAb control followed by incubation with
goat anti-mouse IgG mAb-HRP and developed by ECL.
2.6. Immunoprecipitation of T. cruzi surface proteins with anti-galectin-
3 mAb and immunoblots
For immunoprecipitations, 20 Wg of solubilized biotinylated trypo-
mastigotes were precleared with protein A Sepharose and superna-
tants were incubated with either a rat IgG mAb to galectin-3 or its
isotype control (both diluted 1:10) in immunoprecipitation bu¡er
overnight at 4‡C [20]. Immunoprecipitates were separated by SDS^
PAGE, blotted on nitrocellulose, incubated with avidin^HRP and
developed by ECL. For immunoblotting, 5 Wg of trypomastigote ly-
sates were separated by SDS^PAGE, blotted onto nitrocellulose mem-
branes and strips were probed with either a mAb to human galectin-3
or its isotype mAb control followed by incubation with goat anti-rat
IgG mAb^HRP and developed by ECL.
2.7. Presentation of results and statistical analysis
Results in this work were obtained from triplicate values and rep-
resent three independent experiments with identical protocols. Results
are expressed as the mean þ 1 standard deviation. Di¡erences were
considered to be statistically signi¢cant if P6 0.05 as determined by
Student’s t-test.
3. Results
3.1. Human galectin-3 enhanced T. cruzi trypomastigote
adhesion to laminin but not to collagen
The ability of galectin-3 in promoting adhesion of trypo-
mastigotes to laminin or collagen was investigated. Fig. 1
shows that addition of galectin-3 to coated wells with laminin
dramatically enhanced the adhesion of trypomastigotes to
laminin, whereas galectin-3 did not a¡ect trypomastigote ad-
hesion to collagen. Galectin-3 increased the normal adhesion
of trypanosomes to laminin 20 times and this e¡ect is speci¢c
since it is inhibited by lactose but not by sucrose (Fig. 2).
Furthermore, the lactose induced inhibition of trypanosome
adhesion to laminin, in the presence of exogenous galectin-3,
is concentration dependent and saturable (Fig. 3), thus indi-
cating that the speci¢city of this e¡ect is mediated by the
L-galactoside binding galectin-3. Lactose inhibits the enhance-
ment e¡ect seen at concentrations of 1 Wg/ml, attaining max-
imal inhibition at 25^100 Wg/ml (Fig. 3).
3.2. Human galectin-3 interacts with several surface proteins of
invasive forms of T. cruzi and this interaction is inhibited
by lactose
The ability of galectin-3 to interact with trypomastigote
surface proteins was investigated by incubating solubilized
Fig. 1. Human galectin-3 dramatically enhances T. cruzi trypomasti-
gote adhesion to laminin. Trypomastigotes (2U106) were added to
micro wells coated with either laminin or collagen in the presence
of galectin-3. The number of trypomastigotes bound per 50 ¢elds
was microscopically determined. This is a representative experiment
of three performed. Di¡erences between * and **, P6 0.05.
Fig. 2. The galectin-3 enhanced binding of trypanosomes to laminin
is speci¢cally inhibited by lactose, but not by sucrose. Trypomasti-
gotes (2U106) were added to micro wells coated with laminin in the
presence of galectin-3 supplemented with either 50 Wg/ml of lactose
or sucrose. The number of bound trypanosomes was microscopically
determined. This is a representative experiment of three performed.
Di¡erences between * and **, P6 0.05.
Fig. 3. Lactose inhibits trypanosome adhesion to laminin in the
presence of exogenous galectin-3 in a concentration dependent and
saturable manner. Increasing concentrations of lactose (1^100 Wg/
ml) were added to laminin coated wells in the presence of trypomas-
tigotes (2U106) and galectin-3 (100 Wg/ml) and the number of
bound trypanosomes was determined.
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biotinylated trypomastigotes with galectin-3 in the absence
and presence of lactose or sucrose and co-immunoprecipitat-
ing trypanosome surface proteins bound to galectin-3 using
anti-galectin-3 polyclonal antibodies. Co-immunoprecipitation
assays revealed that galectin-3 binds to the 45, 32 and 30 kDa
surface proteins of trypomastigotes (Fig. 4A, lane 1). Control
pre-immune antibodies did not recruit proteins (Fig. 4A, lane
2). The interaction between galectin-3 and the 45, 32 and
30 kDa trypanosome surface proteins was inhibited by lactose
(Fig. 4A, lane 3), but not by sucrose (Fig. 4A, lane 4). Im-
munoprecipitation controls using polyclonal antibodies to ga-
lectin-3 and solubilized biotinylated trypanosomes indicated
that polyclonal antibodies to galectin-3 recognized the surface
64 and 50 kDa proteins (Fig. 4B, lane 1), whereas pre-immune
antibodies did not (Fig. 4B, lane 2). These results indicate that
the interaction between galectin-3 and the trypanosome 45, 32
and 30 kDa proteins is galectin speci¢c, since galectin^mam-
malian protein interactions are speci¢cally inhibited by lac-
tose.
3.3. Trypanosome surface proteins that interact with galectin-3
are recognized by a mAb to galectin-3
Based on the facts that (a) human galectin-3 molecules can
homodimerize to modulate biological functions in mammalian
hosts [22], and (b) our results indicate that galectin-3 interacts
with several surface molecules of trypanosomes (Fig. 4A, lane
1), we decided to explore the possibility that the trypanosome
surface molecules that interacted with galectin-3 could be ga-
lectin-3 homologues by studying their ability to be immuno-
precipitated by an anti-galectin-3 mAb. Fig. 4C, lane 1, shows
that a mAb to galectin-3 immunoprecipitated surface proteins
of 45 and 32 kDa of the same molecular weight as those that
interacted with galectin-3 (Fig. 4A, lane 1), with the exception
of the 30 kDa protein, whereas an isotype control mAb did
not (Fig. 4C, lane 2). Fig. 4D, lane 1, shows an immunoblot
of trypomastigote lysates probed with an anti-galectin-3 mAb
recognizing proteins of the same molecular weights as those
previously identi¢ed by immunoprecipitations (Fig. 4C) or by
co-immunoprecipitations (Fig. 4A). An isotype control mAb
did not recognize any T. cruzi proteins (Fig. 4D, lane 2). Both
polyclonal antibodies to galectin-3 and a mAb to galectin-3
strongly recognized a major 64 kDa surface protein of trypo-
mastigotes by immunoprecipitations (Fig. 4B, lane 1 and Fig.
4C, lane 1) as well as by immunoblotting (Fig. 4D, lane 1).
These results suggest that the trypanosome surface proteins
(45, 32 and 30 kDa) interact with galectin-3 and present gal-
actosyl binding sites for galectin-3. To identify surface trypo-
mastigote proteins that interact with galectin-3, the blot pre-
sented in lane 1 of Fig. 4A was stripped and probed with
either anti-T. cruzi mucin mAb or its isotype control. Fig.
4E, lane 1, shows that a mAb to T. cruzi mucin recognized
the T. cruzi 45 kDa surface protein, whereas an isotype con-
trol mAb did not (Fig. 4E, lane 2). This indicates that galec-
tin-3 interacts with a 45 kDa surface T. cruzi mucin.
4. Discussion
This study reports a novel mechanism where a human para-
site, T. cruzi, utilizes human galectin-3 to e¡ectively interact
with laminin. Our working model proposes that the exoge-
nously supplied galectin-3 forms bridges between T. cruzi
and laminin. Galectin-3 molecules interact with T. cruzi
Fig. 4. Interactions between galectin-3 and trypomastigote surface proteins, and recognition of trypanosome surface proteins by mAb to galec-
tin-3 or by mAb to T. cruzi mucin. A: Co-immunoprecipitations of trypomastigote surface proteins with galectin-3 using anti-galectin-3 poly-
clonal antibodies. Solubilized biotinylated trypomastigotes (100 Wg) and galectin-3 (100 Wg) were incubated together, as well as in the presence
of either lactose or sucrose. The trypanosome surface proteins bound to galectin-3 were co-immunoprecipitated using polyclonal antibodies to
galectin-3 or pre-immune antibodies. Biotinylated trypanosome surface proteins bound to galectin-3 were separated by SDS^PAGE, blotted
onto nitrocellulose membranes and developed by ECL. B: Immunoprecipitation controls of solubilized biotinylated trypomastigotes (20 Wg) us-
ing either anti-galectin-3 polyclonal antibodies or pre-immune antibodies in the absence of galectin-3. Immunoprecipitated proteins were blotted
and developed by ECL. C: Immunoprecipitations of T. cruzi surface proteins using anti-galectin-3 mAb. Solubilized biotinylated trypomasti-
gotes (20 Wg) were incubated with either a mAb to galectin-3 or a mAb isotype control. Immunoprecipitated proteins were blotted and devel-
oped by ECL. D: Immunoblotting of T. cruzi lysates probed with anti-galectin-3 mAb. 5 Wg of trypomastigote lysates were separated, blotted
and probed with either anti-human galectin-3 mAb or its isotype control mAb and developed by ECL. E: An immunoblot prepared by strip-
ping the blot in lane 1 of A and probing with either anti-T. cruzi mucin mAb or its isotype control mAb and developing by ECL.
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45 (mucin), 32 and 30 kDa surface proteins on one hand and
with laminin on the other, via their carbohydrate recognition
domains and are joined together using the R-domains [13] in a
concentration dependent manner. Therefore, depending on
the level of secretion, T. cruzi galectin-3 homologues may
also directly ligate trypanosomes to laminin. Since nearly all
the tissues which T. cruzi infects are surrounded by basement
membranes of which laminin is a major constituent, its ability
to e¡ectively interact with laminin is critically important for
passage through the membrane barrier. Our studies suggest
that this is a trypanosome trapping mechanism which enables
the organisms to accumulate in the basement membrane prior
to invasion, making galectin-3 a candidate molecule which
enhances the pathogenesis of T. cruzi.
Whereas it was expected for the anti-galectin-3 mAb to
recognize one protein band (V30 kDa) in the immunoblot,
several minor bands were detected and a major band at
around 64 kDa. Additional evidence supporting the ¢nding
that the 64 kDa band was the major band recognized was
obtained from immunoprecipitations using both anti-galec-
tin-3 mAb and polyclonal antibodies. It is likely that the 32
kDa band is the T. cruzi homologue of the human galectin-3.
The 64 kDa band may represent the dimerized form of a
galectin-3 homologue or the heterodimer formed between a
galectin-3 homologue and a homologue of the 37 kDa laminin
binding protein [23]. Similarly the 97 kDa band may represent
a multimeric form of galectin-3. Although the heterogeneity
resulting from galectin-3 cross-reacting molecules is not com-
mon in mammalian cells, the V64 kDa and the 45 kDa band
are occasionally observed as minor cross-reacting bands with
this mAb in Western blots of mammalian cell lysates (unpub-
lished observations). This may be a reason why this mAb
reacts with the T. cruzi 45 kDa mucin. Interestingly, exoge-
nously supplied galectin-3 was able to co-precipitate three
trypanosome surface proteins in the immunoprecipitation ex-
periments. This study also shows that one of the surface mol-
ecules of T. cruzi that interacts with galectin-3 is a T. cruzi 45
kDa mucin. T. cruzi complex family of mucins has been re-
ported [15]. However, the genes, the identity and biochemical
properties of the 32 and 30 kDa surface receptors for galectin-
3 in T. cruzi are unknown and therefore warrant extensive
investigation. So far, galectin genes in T. cruzi have not
been reported. The interaction of galectin-3 with mammalian
cell surface mucins has been demonstrated. Studies by Bresa-
lier et al. [24] demonstrated that galectin-3 binds to colon
cancer mucins in a lactose dependent manner.
Galectins have long been suspected of modulating cell to
extracellular matrix interactions in a novel fashion [6,25,26].
Data from various laboratories suggest that one mechanism
used involves the ligation of mammalian cells to extracellular
matrix proteins which also interact with galectin-3 such as
laminin and elastin [27,28] according to the model suggested.
The other mechanism involves the interaction of galectins
with the polylactosamine residues in integrins, resulting in
the modulation of cellular adhesion to extracellular matrix
proteins [16,29]. Whereas most of these studies have been
done in mammalian systems, it has been suggested that galec-
tins expressed by Entamoeba may be critical in their interac-
tions with host cells [30]. It is likely that in parasitic organ-
isms, the ligation of the organisms to the extracellular matrix
proteins or cell surface glycoconjugates may be the primary
adhesion mechanisms mediated by galectins.
In summary, we have demonstrated that human galectin-3
modulates the interaction of T. cruzi with laminin in a lactose
dependent manner. There are several surface molecules in
T. cruzi that interact with galectin-3 which are involved in
the ligation of the parasite to laminin.
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